Galmed Pharmaceuticals Stock Net Income
| GLMD Stock | USD 0.79 0 0.13% |
As of the 27th of January, Galmed Pharmaceuticals retains the Market Risk Adjusted Performance of (0.57), risk adjusted performance of (0.1), and Standard Deviation of 5.22. Galmed Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Galmed Pharmaceuticals standard deviation, treynor ratio, as well as the relationship between the Treynor Ratio and potential upside to decide if Galmed Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 0.79100001 per share. As Galmed Pharmaceuticals is a penny stock we also advise to confirm its jensen alpha numbers.
Galmed Pharmaceuticals Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -6.8 M | -7.1 M | |
| Net Loss | -6.8 M | -7.1 M | |
| Net Loss | -25.9 M | -24.6 M | |
| Net Loss | (9.29) | (9.75) | |
| Net Income Per E B T | 1.20 | 1.09 |
Galmed | Net Income | Build AI portfolio with Galmed Stock |
Latest Galmed Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Galmed Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Galmed Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Galmed Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Galmed Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Galmed Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (7.52 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Galmed Net Income Regression Statistics
| Arithmetic Mean | (12,396,051) | |
| Coefficient Of Variation | (67.70) | |
| Mean Deviation | 6,674,317 | |
| Median | (9,856,000) | |
| Standard Deviation | 8,392,217 | |
| Sample Variance | 70.4T | |
| Range | 28.8M | |
| R-Value | (0.24) | |
| Mean Square Error | 71T | |
| R-Squared | 0.06 | |
| Significance | 0.36 | |
| Slope | (391,421) | |
| Total Sum of Squares | 1126.9T |
Galmed Net Income History
Other Fundumenentals of Galmed Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Galmed Pharmaceuticals Net Income component correlations
Galmed Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Galmed Pharmaceuticals is extremely important. It helps to project a fair market value of Galmed Stock properly, considering its historical fundamentals such as Net Income. Since Galmed Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Galmed Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Galmed Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Galmed Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Galmed Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Galmed Pharmaceuticals.
| 10/29/2025 |
| 01/27/2026 |
If you would invest 0.00 in Galmed Pharmaceuticals on October 29, 2025 and sell it all today you would earn a total of 0.00 from holding Galmed Pharmaceuticals or generate 0.0% return on investment in Galmed Pharmaceuticals over 90 days. Galmed Pharmaceuticals is related to or competes with Biovie, Theriva Biologics, Moolec Science, Chemomab Therapeutics, InMed Pharmaceuticals, Biodexa Pharmaceticals, and Virax Biolabs. Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for ... More
Galmed Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Galmed Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Galmed Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 21.39 | |||
| Value At Risk | (9.20) | |||
| Potential Upside | 8.04 |
Galmed Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Galmed Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Galmed Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Galmed Pharmaceuticals historical prices to predict the future Galmed Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.1) | |||
| Jensen Alpha | (0.86) | |||
| Total Risk Alpha | (1.27) | |||
| Treynor Ratio | (0.58) |
Galmed Pharmaceuticals January 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | (0.57) | |||
| Mean Deviation | 3.92 | |||
| Coefficient Of Variation | (687.63) | |||
| Standard Deviation | 5.22 | |||
| Variance | 27.24 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.86) | |||
| Total Risk Alpha | (1.27) | |||
| Treynor Ratio | (0.58) | |||
| Maximum Drawdown | 21.39 | |||
| Value At Risk | (9.20) | |||
| Potential Upside | 8.04 | |||
| Skewness | (0.08) | |||
| Kurtosis | 0.6511 |
Galmed Pharmaceuticals Backtested Returns
Galmed Pharmaceuticals holds Efficiency (Sharpe) Ratio of -0.14, which attests that the entity had a -0.14 % return per unit of risk over the last 3 months. Galmed Pharmaceuticals exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Galmed Pharmaceuticals' Risk Adjusted Performance of (0.1), market risk adjusted performance of (0.57), and Standard Deviation of 5.22 to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 1.33, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Galmed Pharmaceuticals will likely underperform. At this point, Galmed Pharmaceuticals has a negative expected return of -0.74%. Please make sure to check out Galmed Pharmaceuticals' total risk alpha, daily balance of power, relative strength index, as well as the relationship between the potential upside and day typical price , to decide if Galmed Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.54 |
Modest predictability
Galmed Pharmaceuticals has modest predictability. Overlapping area represents the amount of predictability between Galmed Pharmaceuticals time series from 29th of October 2025 to 13th of December 2025 and 13th of December 2025 to 27th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Galmed Pharmaceuticals price movement. The serial correlation of 0.54 indicates that about 54.0% of current Galmed Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.54 | |
| Spearman Rank Test | 0.62 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Galmed Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Galmed Pharmaceuticals reported net income of (7.52 Million). This is 102.2% lower than that of the Biotechnology sector and 110.73% lower than that of the Health Care industry. The net income for all United States stocks is 101.32% higher than that of the company.
Galmed Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Galmed Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Galmed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Galmed Pharmaceuticals by comparing valuation metrics of similar companies.Galmed Pharmaceuticals is currently under evaluation in net income category among its peers.
Galmed Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Galmed Pharmaceuticals from analyzing Galmed Pharmaceuticals' financial statements. These drivers represent accounts that assess Galmed Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Galmed Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 793.8M | 536.9M | 150.8M | 3.0M | 3.4M | 3.2M | |
| Enterprise Value | 787.1M | 534.3M | 148.8M | (1.7M) | (1.9M) | (1.8M) |
Galmed Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Galmed Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Galmed Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Galmed Pharmaceuticals' value.| Shares | Td Waterhouse Canada Inc | 2025-06-30 | 2.0 | Zrc Wealth Management, Llc | 2025-06-30 | 1.0 | Dogwood Wealth Management Llc | 2025-06-30 | 1.0 | Tower Research Capital Llc | 2025-03-31 | 0.0 | Virtu Financial Llc | 2025-06-30 | 0.0 | Two Sigma Securities, Llc | 2025-06-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 33.6 K | Schonfeld Strategic Advisors Llc | 2025-03-30 | 23.2 K | Cambridge Invest Research Advisors, Inc. | 2025-06-30 | 10.1 K | Ubs Group Ag | 2025-06-30 | 6.9 K | Sbi Securities Co Ltd | 2025-06-30 | 2.1 K |
Galmed Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | (8.14 M) | ||||
| Shares Outstanding | 5.48 M | ||||
| Shares Owned By Insiders | 0.91 % | ||||
| Shares Owned By Institutions | 1.04 % | ||||
| Number Of Shares Shorted | 73.08 K | ||||
| Price To Earning | (6.79) X | ||||
| Price To Book | 0.23 X | ||||
| EBITDA | (7.42 M) | ||||
| Net Income | (7.52 M) | ||||
| Cash And Equivalents | 22.4 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 2.17 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.48 X | ||||
| Book Value Per Share | 3.49 X | ||||
| Cash Flow From Operations | (5.88 M) | ||||
| Short Ratio | 0.49 X | ||||
| Earnings Per Share | (3.44) X | ||||
| Target Price | 12.0 | ||||
| Beta | 0.35 | ||||
| Market Capitalization | 4.47 M | ||||
| Total Asset | 18.5 M | ||||
| Retained Earnings | (200.47 M) | ||||
| Working Capital | 13.95 M | ||||
| Current Asset | 23.38 M | ||||
| Current Liabilities | 2.54 M | ||||
| Net Asset | 18.5 M |
About Galmed Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Galmed Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Galmed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Galmed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| HITI | High Tide | |
| HITI | High Tide | |
| BAC | Bank of America |
Check out Galmed Pharmaceuticals Piotroski F Score and Galmed Pharmaceuticals Altman Z Score analysis. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.